Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

Leveraging probiotic-derived membrane vesicles as a postbiotic therapeutic for Crohn's disease

FY 2022-23

Summary
It is estimated that the population of bacteria that live in our gut, known as the gut microbiota, outnumber the cells of the human body 100 times. The diversity of microbial species and their capabilities is so immense that we have only scratched the surface into understanding the relationship between humans and their gut microbiota. Over the past few decades, we have uncovered that this relationship is linked to numerous aliments including inflammatory bowel disease (IBD), diabetes, cancer, and anxiety disorders. With our expanding knowledge of human-microbe communication, the development of probiotic therapies for these aliments is an exciting and promising new venture. Probiotics are living microorganisms that when consumed can provide health benefits. Crohn's disease (CD) is a form of IBD that is characterized by chronic and relapsing inflammation of the digestive system. Over 135,000 Canadians live with CD; this is one of the highest rates of CD in the world. With our current therapeutics, it is estimated that 75% of CD patients still require surgery during their lifetime. While the driving causes of CD are unknown, our understanding involves factors such as the gut microbiota, integrity of the gut barrier, and genetic predisposition. In CD, communication between the patient and their gut microbiota is disrupted. This communication is important to strengthen and repair the gut barrier. My research aims to develop new therapeutics for CD that restores this therapeutic communication pathway. I am using genetic engineering technology to design probiotics that will deliver beneficial microbial products to gut cells. My work will help to further the understanding of human-microbe communication and work towards improving the therapeutic outcomes of patients with CD.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
475656
Name
Baerg Lauren
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Leveraging probiotic-derived membrane vesicles as a postbiotic therapeutic for Crohn's disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Bacterial Membrane Vesciles; Crohn'S Disease; Drug Delivery; Intestinal Repair; Metabolic Engineering; Nod2 Receptor; Organoid Models; Postbiotics
Abstract
It is estimated that the population of bacteria that live in our gut, known as the gut microbiota, outnumber the cells of the human body 100 times. The diversity of microbial species and their capabilities is so immense that we have only scratched the surface into understanding the relationship between humans and their gut microbiota. Over the past few decades, we have uncovered that this relationship is linked to numerous aliments including inflammatory bowel disease (IBD), diabetes, cancer, and anxiety disorders. With our expanding knowledge of human-microbe communication, the development of probiotic therapies for these aliments is an exciting and promising new venture. Probiotics are living microorganisms that when consumed can provide health benefits. Crohn's disease (CD) is a form of IBD that is characterized by chronic and relapsing inflammation of the digestive system. Over 135,000 Canadians live with CD; this is one of the highest rates of CD in the world. With our current therapeutics, it is estimated that 75% of CD patients still require surgery during their lifetime. While the driving causes of CD are unknown, our understanding involves factors such as the gut microbiota, integrity of the gut barrier, and genetic predisposition. In CD, communication between the patient and their gut microbiota is disrupted. This communication is important to strengthen and repair the gut barrier. My research aims to develop new therapeutics for CD that restores this therapeutic communication pathway. I am using genetic engineering technology to design probiotics that will deliver beneficial microbial products to gut cells. My work will help to further the understanding of human-microbe communication and work towards improving the therapeutic outcomes of patients with CD.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Baerg, Lauren
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~